AI Article Synopsis
Article Abstract
Introduction: The gravest problem facing medicine is caring for an aging society and the comorbidities that develop with age, including an increasing prevalence of cardiac disease. Unrecognized or untreated cardiac disease increases the risk of complications in patients undergoing laparoscopic liver resection (LLR). We herein describe the preoperative status, perioperative outcomes, and postoperative courses of patients with or without cardiac disease who undergo LLR.
Material And Methods: The data of 339 patients who underwent LLR at a single institution between 2010 and 2018 were retrospectively reviewed. Their preoperative status, surgical outcomes, and postoperative courses were analyzed.
Results: Of 339 patients who underwent LLR, one was excluded for pre-existing severe valvular disease. Of the remaining 338 patients, 16 had coexisting cardiac disease and 322 did not. The patients with coexisting cardiac disease had a mean left ventricular ejection fraction of 66% (22-74%). LLR was performed after cardiac function was controlled in the patients with cardiac disease; there were no instances of increased central venous pressure (CVP) or destabilized vital signs during surgery. Intraoperative CVP did not differ between the groups ( = 0.521). There were no significant differences in the demographics except for age, operative characteristics, and surgical outcomes between the groups.
Conclusions: Patients with non-severe or controlled severe cardiac disease do not exhibit different postoperative courses compared to patients without coexisting cardiac disease. Uncontrolled severe cardiac disease can lead to unstable vital signs during surgery, such as increased CVP. In such cases, treating the cardiac disease should be prioritized.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500396 | PMC |
| http://dx.doi.org/10.5114/wo.2019.84109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High Shear Stress Reduces ERG Causing Endothelial-Mesenchymal Transition and Pulmonary Arterial Hypertension.
Arterioscler Thromb Vasc Biol
December 2024
Department of Pediatrics (T.S., J.-R.M., Y.H.C., J.M.S., J. Kaplan, A.C., L.W., D.G., S.T., S.I., M.D., W.Y., A.L.M., M.R.).
Background: Computational modeling indicated that pathological high shear stress (HSS; 100 dyn/cm) is generated in pulmonary arteries (PAs; 100-500 µm) in congenital heart defects causing PA hypertension (PAH) and in idiopathic PAH with occlusive vascular remodeling. Endothelial-to-mesenchymal transition (EndMT) is a feature of PAH. We hypothesize that HSS induces EndMT, contributing to the initiation and progression of PAH.
View Article and Find Full Text PDFThe polycomb protein complex interacts with GATA-6/PPARα to inhibit α-MHC expression.
Dev Growth Differ
December 2024
Department of Biochemistry & Molecular Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Transcription factors collaborate with epigenetic regulatory factors to orchestrate cardiac differentiation for heart development, but the underlying mechanism is not fully understood. Here, we report that GATA-6 induces cardiac differentiation but peroxisome proliferator-activated receptor α (PPARα) reverses GATA-6-induced cardiac differentiation, possibly because GATA-6/PPARα recruits the polycomb protein complex containing EZH2/Ring1b/BMI1 to the promoter of the cardiac-specific α-myosin heavy chain (α-MHC) gene and suppresses α-MHC expression, which ultimately inhibits cardiac differentiation. Furthermore, Ring1b ubiquitylates PPARα and GATA-6.
View Article and Find Full Text PDFEstablishing a Novel Animal Model of Tricuspid Regurgitation by Self-expanding Stent.
Ann Ital Chir
December 2024
Department of Cardiovascular Surgery, Shaoxing People's Hospital, 312000 Shaoxing, Zhejiang, China.
Aim: To establish a simple, safe, and reproducible animal model of tricuspid regurgitation (TR).
Methods: A self-expanding stent made of nickel-titanium shape memory metal alloy was developed. Ten white pigs were randomized into an experimental group (n = 7) and a control group (n = 3).
"Letter to the Editor: A Correction to [Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation]".
Clin Cardiol
January 2025
Alexandria University, Alexandria faculty of Medicine, Champollion street, Alexandria, Egypt.
We recently reviewed the article titled "Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation" published in Clinical Cardiology by [khan et al.] (1) with great interest. This study addresses a crucial area of clinical practice, and we appreciate the authors' efforts in exploring this topic.
View Article and Find Full Text PDFAssessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.
Diabetes Obes Metab
December 2024
The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Aim: To comprehensively evaluate the benefits and risks of glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase 4 inhibitors (DPP4i), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Materials And Methods: A systematic search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to November 2023 to identify randomized cardiovascular and kidney outcome trials that enrolled adults with type 2 diabetes, heart failure, or chronic kidney disease and compared DPP4i, GLP-1RAs, or SGLT2i to placebo. Twenty-one outcomes (e.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!